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The food grade bacterium Lactococcus lactis is a potential vehicle for protein delivery in the gastrointestinal
tract. As a model, we constructed lactococcal strains producing antigens of infectious bursal disease virus
(IBDV). IBDV infects chickens and causes depletion of B-lymphoid cells in the bursa of Fabricius and
subsequent immunosuppression, morbidity, or acute mortality. The two major IBDV antigens, i.e., VP2 and
VP3, that form the viral capsid were expressed and targeted to the cytoplasm, the cell wall, or the extracellular
compartment of L. lactis. Whereas VP3 was successfully targeted to the three compartments by the use of
relevant expression and export vectors, VP2 was recalcitrant to export, thus confirming the difficulty of
translocating naturally nonsecreted proteins across the bacterial membrane. This defect could be partly
overcome by fusing VP2 to a naturally secreted protein (the staphylococcal nuclease Nuc) that carried VP2
through the membrane. Lactococcal strains producing Nuc-VP2 and VP3 in various bacterial compartments
were administered orally to chickens. The chickens did not develop any detectable immune response against
VP2 and VP3 but did exhibit an immune response against Nuc when Nuc-VP2 was anchored to the cell wall of
lactococci.
Lactic acid bacteria (LAB) constitute an important group of
industrial microorganisms that have long been used for fer-
mentation and preservation of a broad range of food products.
Intensive studies of the fundamental mechanisms of LAB bi-
ology in physiology and genetics have provided opportunities
for the use of these bacteria in new applications (26, 41). One
of them is the use of LAB as vehicles with which to deliver
biologically active molecules such as enzymes, antigens, or
therapeutic drugs into humans and animals.
One of the most investigated and challenging new fields of
application for LAB is their use as antigen delivery vehicles for
mucosal immunization (29, 41, 49). The mucosa, which pro-
vides areas of contact with the outside environment, is the
entry route of many pathogens, including viruses, bacteria, and
parasites. Pathogen proliferation and/or penetration on or
through mucosal surfaces is prevented by (i) the physical bar-
rier provided by the mucosal epithelium itself and by the mu-
cosal physicochemical environment (mucus layer, peristalsis,
acidity, enzymes), (ii) the normal mucosal microflora that pre-
vents development of exogenous microorganisms, and (iii) the
mucosal immune system. While the first two mechanisms are
nonspecific, the mucosal immune system is highly specialized
and involves different types of cells that establish specific re-
sponses against pathogens (22). The mucosal immune re-
sponse is characterized by the synthesis of large amounts of
class A immunoglobulins (IgA) that are secreted onto the
mucosal surfaces and have a major role in the clearance of
pathogens (9). Mucosal (as well as systemic) immunization can
be achieved by presenting antigens at mucosal sites. LAB are
well suited for this purpose. They are organisms that are gen-
erally regarded as safe and are regularly and widely ingested by
humans and animals through food products, and many LAB
species are members of the normal gut microflora of humans
and animals.
An intermediate step for the use of LAB in new applica-
tions, such as vaccine delivery, is the development of expres-
sion systems for stable production of heterologous proteins.
We have recently designed a protein-targeting system that al-
lows the targeting of a reporter protein to the cytoplasm, the
cell wall, or the extracellular medium of various LAB species
(10). With this system, we are investigating the potential of the
best-characterized LAB, Lactococcus lactis, to be used as a live
mucosal vaccine against chicken infectious bursal disease virus
(IBDV). IBDV is the causative agent of a highly contagious
chicken disease known as Gumboro (42). It belongs to the
family of Birnaviridae, which consists of naked viruses charac-
terized by a bisegmented, bistranded RNA genome (11). The
largest double-stranded segment (segment A) harbors an open
reading frame that encodes a precursor polyprotein. Its self-
processing yields viral proteins VP2, VP3, and VP4 (21). VP2
and VP3 form the viral capsid of IBDV, and VP4 is the mat-
uration protease of the polyprotein. IBDV infects young chick-
ens through the digestive tract and massively destroys B cells in
the bursa of Fabricius, a primary lymphoid organ, causing
immunosuppression and death. Surviving birds are severely
immunocompromised and more susceptible to other avian
pathogens (38). IBDV is therefore of major concern in the
poultry industry. Vaccination methods currently used in poul-
try industries consist of individual subcutaneous or intramus-
cular injection of inactivated IBDV into birds (1). A method
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that incorporates the vaccine in the drinking water also exists,
but this method is only effective when live (attenuated) IBDV
strains are used. Infection with these vaccine strains results in
bursa damage. In the case of the more potent vaccine, severe
depletion of B-lymphoid cells is observed, which results in
immunosuppression, leading to an impaired immune response
to other vaccinations and greater vulnerability to opportunistic
infections (1, 31). Alternatively, both recombinant vaccines
and DNA vaccines against IBDV are under investigation (6,
27).
Here we report the expression of the major IBDV antigens
VP2 and VP3 in L. lactis. VP2 and VP3 were targeted to the
cytoplasm, the cell wall, and the culture medium of L. lactis.
The recombinant lactococci were used for oral immunization
of chickens, and the immune response was monitored. In this
first report of a trial that used antigens producing LAB in
production animals such as chickens, possible improvements of
this vaccination strategy are discussed.
MATERIALS AND METHODS
Bacterial strains, plasmids, and media. The bacterial strains and plasmids
used in this study are listed in Table 1. Escherichia coli strains were grown in
Luria broth (39) supplemented with thymine at 37°C with shaking. L. lactis
strains were grown in M17 medium (46) at 30°C without shaking. When appro-
priate, antibiotics were added as follows: for E. coli, erythromycin (150 g/ml)
and ampicillin (100 g/ml); for L. lactis, erythromycin (5 g/ml).
DNA manipulation and transformation procedures. General molecular biol-
ogy techniques were performed essentially as previously described (39). Plasmid
DNA was extracted as previously described for E. coli (4) and L. lactis (33).
Plasmids were established in L. lactis by electroporation (24) and in E. coli by
heat shock (39).
Cloning of IBDV segment A cDNA. We used cDNA from highly virulent IBDV
strain D6948 (5). Generation of the full-length cDNA of segment A was previ-
ously described (5). The cDNA was cloned into a pGEM-T vector (Promega),
and the resulting pHB22 plasmid was established in E. coli (5).
Cloning strategy in L. lactis. We previously designed vectors that allowed the
targeting of Staphylococcus aureus nuclease (Nuc) to the cytoplasm, the cell wall,
and the medium of L. lactis cultures (10). In those vectors, the nuc gene is
flanked by unique SalI and EcoRV sites at its 5 and 3 ends, respectively. To
clone genes encoding the IBDV antigens, we replaced nuc in the targeting
vectors with vp2 and vp3 after SalI and EcoRV digestion.
Cloning of vp3. The vp3 gene was PCR amplified from pHB22 (5) with primers
VP3a (5 CGCGACTGTCGACCGTTTTCCTCACAATCCA) and VP3b (5 GC
CAGTCGATATCTCCTCAAGGTCCTCATCAGA). The latter unraveling of
the exact cleavage site between VP3 and VP4 indicated that these primers
actually amplify a portion of vp4 resulting in the addition of 33 amino acids from
VP4 to the N terminus of VP3 (25). VP3a bears a SalI site (in bold) at the 5 end
of the sequence derived from the vp3 gene and a tail (in italics) at its 5 terminus.
VP3b harbors an EcoRV site (in bold) adjacent to the sequence derived from the
vp3 gene and a 5 tail (in italics). The PCR product was digested with SalI and
EcoRV and cloned into SalI- and EcoRV-digested pVE5523 (secretion vector),
pVE5524 (cell wall anchoring vector), and pVE5529 (cytoplasmic vector) to yield
plasmids pVE5541, pVE5542, and pVE5543, respectively. These plasmids were
then used to transform L. lactis cells.
Cloning of vp2. The vp2 gene was PCR amplified from plasmid pHB22 with
primers VP2a (5GGTCGGAGTCGACTGGTTAGTAGAGATCAGACAAA
[the SalI site is shown in bold, and the 5 tail is in italics]) and VP2b (5GCCA
GTCGATATCTCCCTTAGGGCCCGGATTA [the EcoRV site is in bold, and
the 5 tail is in italics]). The PCR product was restricted with SalI and EcoRV
and cloned into pVE5529, pVE5523, and pVE5524 digested with the same
enzymes to yield plasmids pVE5588, pVE5586, and pVE5587, respectively. To
construct pVE5539, which harbors the spUsp45-nuc-vp2, plasmid pVE5586 was
linearized with SalI and then treated with mung bean nuclease. A second diges-
tion with NheI generated a 4,071-bp fragment that was ligated to the 5,656-bp
EcoRV-NheI fragment of pVE5523. To construct pVE5540, which harbors the
spUsp45-nuc-vp2-cwaM6 fusion, pVE5587 was linearized with SalI, treated with
mung bean nuclease, and digested with BsgI. The resulting 2,643-bp fragment
was ligated to the 7,618-bp EcoRV-BsgI fragment from pVE5524.
Cell fractionation, protein extraction, and Western blot analysis. Medium, cell
wall, and protoplast fractionation and protein extractions were performed as
previously described (33). Briefly, 2 ml of exponential-phase cultures (optical
density at 600 nm [OD600], 0.6 to 0.8) was microcentrifuged at 4°C for 3 min at
15,000  g. The supernatant and the cell pellet were processed separately. The
supernatant was filtered through 0.2-m-pore-size filters (low protein retention;
Millipore) for bacterial removal, and proteins from 1.6 ml of the filtrate were
precipitated with 400 l of ice-cold 80% (wt/vol) trichloroacetic acid (16% final
concentration). The mixture was kept on ice for 20 min and then microcentri-
fuged at 4°C for 15 min at 15,000  g. The resulting pellet was dissolved at 80 l
per OD600 unit in 50 ml of NaOH containing 4-(2-aminoethyl)benzenesulfonyl
fluoride hydrochloride (AEBSF; 2 mM) as a protease inhibitor. The cell pellet
was washed once with TES (10 mM Tris-HCl [pH 5.8], 1 mM EDTA, 25%
sucrose) containing chloramphenicol (50 g/ml) as an inhibitor of protein syn-
thesis. The bacterial cell walls were digested with 500 l of TES containing
lysozyme (0.5 mg/ml), mutanolysin (0.1 mg/ml), RNase (0.1 mg/ml), and AEBSF
(2 mM). After 1 h of incubation at 37°C, the protoplasts were recovered by a
3-min centrifugation at 15,000  g and 4°C and then washed with TES plus
TABLE 1. Bacterial strains and plasmids used in this study
Strain or plasmid Relevant characteristicsa Source orreference
Strains
E. coli TG1 39
L. lactis MG1363 Plasmid-free strain 16
Plasmids
pHB-22R Apr; A-segment cDNA of IBDV strain D6948 cloned into pGEM-T (Promega) 5
pVE5506 Emr; pIL252 derivative 10
pVE5523 Apr Emr; pBS::pIL252::ttrpA::P59::spUsp45-nucA-t1t2 10
pVE5524 Apr Emr; pBS::pIL252::ttrpA::P59::spUsp45-nucA-cwaM6-t1t2 10
pVE5529 Apr Emr pBS::pIL252::ttrpA::P59::nucA-t1t2 10
pVE5588 Apr Emr; pBS::pIL252::ttrpA::P59::vp2-t1t2 This work
pVE5539 Apr Emr; pBS::pIL252::ttrpA::P59::spUsp45-nucA-vp2-t1t2 This work
pVE5586 Apr Emr; pBS::pIL252::ttrpA::P59::spUsp45-vp2-t1t2 This work
pVE5540 Apr Emr; pBS::pIL252::ttrpA::P59::spUsp45-nucA-vp2-cwaM6-t1t2 This work
pVE5587 Apr Emr; pBS::pIL252::ttrpA::P59::spUsp45-vp2-cwaM6-t1t2 This work
pVE5541 Apr Emr; pBS::pIL252::ttrpA::P59::spUsp45-vp3-t1t2 This work
pVE5542 Apr Emr; pBS::pIL252::ttrpA::P59::spUsp45-vp3-cwaM6-t1t2 This work
pVE5543 Apr EMr; pBS::pIL252::ttrpA::P59::vp3-t1t2 This work
a pBS refers to pBSII-KS (Stratagene), ttrpA refers to the trpA operon terminator of E. coli (8), P59 refers to a lactococcal promoter (48), spUsp45 refers to the signal
peptide of Usp45 (47), nucA refers to the A form of staphylococcal nuclease (30), and t1t2 refers to the rrnB operon terminators of E. coli (32).
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chloramphenicol. The pellet was resuspended at 100 l per OD600 unit in Tris-
HCl [pH 7.4]–1 mM EDTA (TE) containing 1% sodium dodecyl sulfate (SDS)
for protoplast lysis. The digested cell walls were recovered from the supernatant
of the above-described centrifugation and filtered through 0.2-m-pore-size fil-
ters, and proteins from 400 l were precipitated with 16% trichloroacetic acid as
described above. The resulting pellet was dissolved at 80 l per OD600 unit in 50
mM NaOH containing 2 mM AEBSF. Equal volumes of 2 loading buffer were
added to all samples. Extracts were subjected to SDS-polyacrylamide gel elec-
trophoresis (12% acrylamide) (23). Electroblotting on polyvinylidene difluoride
membranes (Millipore) and antibody reactions and detection (enhanced chemi-
luminescence) were performed in accordance with the manufacturer’s recom-
mendations. Relative amounts of VP2 and VP3 in the different fractions were
determined by scanning Western blots on a PhosphorImager (Amersham). Anti-
NucA polyclonal antibodies were kindly provided by James Miller. Preparation
of 9.7 anti-VP3 monoclonal antibodies was done as described elsewhere (5).
Anti-VP2 monoclonal antibodies were a kind gift of H. Mueller.
Chicken immunization. Six groups of 10 specific-pathogen-free chickens were
housed separately. At the age of 28 days, each chicken in each group received
orally 1 ml of M17 containing 109 viable lactococci for 5 consecutive days. At the
age of 42 days, each chicken of each group again received orally 1 ml of M17
containing the same 109 viable lactococci for 5 consecutive days. Blood samples
were taken from each chicken when it was 28, 42, and 49 days old. Group 1
received VE5611 (secreted NucA), group 2 received VE5612 (cell wall-anchored
NucA), group 3 received VE5662 (secreted VP3), group 4 received VE5663 (cell
wall-anchored VP3), group 5 received VE5670 (secreted Nuc-VP2 fusion), and
group 6 received VE5671 (cell wall-anchored Nuc-VP2). Sera of the collected
samples were stored at 20°C and analyzed for the presence of IgG antibodies
against NucA, IBDV (IDEXX), and VP3 by enzyme-linked immunosorbent
assay.
RESULTS
We have recently designed a protein-targeting system that
allows the expression of a heterologous enzyme, staphylococcal
Nuc, at three cellular locations in L. lactis and other LAB (10).
The system comprises (i) the strong lactococcal promoter P59
(48), (ii) the signal peptide from Usp45, the major secreted
protein in L. lactis (47) for the secretion of fusion proteins, and
(iii) the cell wall anchor motif from Streptococcus pyogenes M6
protein (19) for sortase-mediated cell wall anchoring (28). The
combination of these tools enabled the design of vectors suit-
able for the expression of Nuc in the cytoplasm, the cell wall,
or the culture medium of LAB; the vectors are designated
below as cytoplasmic, cell wall-anchoring, and secretion vec-
tors, respectively (Fig. 1). In an attempt to target IBDV anti-
gens in L. lactis, we cloned the genes encoding VP2 and VP3
into these vectors.
VP3 can be targeted to three cell compartments in L. lactis.
A PCR fragment specifying the vp3 gene was cloned into the
cytoplasmic, the secretion, and the cell wall-anchoring vectors.
The resulting plasmids were established in L. lactis cells, and
the expression of fusion proteins was analyzed by Western
blotting. Protoplast, cell wall, and supernatant fractions pre-
pared from log-phase cultures were subjected to SDS-poly-
acrylamide gel electrophoresis and revealed with polyclonal
antibodies raised against VP3.
(i) Cytoplasmic-fraction targeting. One band with the ex-
pected size of VP3 (33 kDa) was detected in the protoplast
fraction (Fig. 2A). As expected, no signal was revealed in
either the cell wall or the supernatant fraction. This validates
the protocol used for protein fractionation in that no cytoplas-
mic proteins leak into the cell wall and supernatant fractions.
(ii) External-medium targeting. In the protoplast fraction of
cells harboring the VP3 secretion vector, one major band that
corresponds in size to the SPUsp45-VP3 precursor (37 kDa)
accounted for about 20% of the total signals detected (Fig.
2B). One additional faint band that corresponded in size to
mature VP3 (34 kDa) released from the SPUsp45-VP3 precur-
sor and a smear indicating additional cytoplasmic degradation
of VP3 were revealed. No signal was detected in the cell wall
fraction of cells expressing the secreted fusion of VP3. The two
upper bands migrated more slowly than the control viral VP3,
possibly because of 45 additional amino acids at the N termi-
nus of the recombinant VP3 protein: in the SPUsp45-VP3 con-
struct, 12 amino acids were introduced downstream of the
cleavage site of the Usp45 signal peptide in order to both
improve secretion efficiency and create cloning sites (10); also,
33 amino acids derived from the adjacent VP4 protein in the
IBDV polyprotein were included. About 80% of the signal was
present in the supernatant fraction as one major band and
three lower-molecular-weight bands (Fig. 2B). The largest
band that migrated at a distance similar to that of the faint
FIG. 1. Fusion genes constructed and expressed and presumed cell localization of IBDV antigens. P59, lactococcal promoter; spUsp45, signal
sequence from the Usp45 preprotein; vp, structural gene for viral protein VP2 or VP3; cwaM6, sequence specifying the cell wall anchor domain
from the M6 preprotein; t1t2, transcriptional terminators.
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band in the protoplast fraction corresponds to VP3. The sec-
ond lower band detected in the supernatant fraction is most
likely a degradation product of the higher band. Probably, the
amino acid tails introduced at the N terminus of VP3 are highly
susceptible to proteolysis because of a folding defect. Addi-
tional proteolysis targeted sites within the VP3 sequence and
yielded two additional degradation products. From this hy-
pothesis, the two higher bands that reflect the whole VP3
sequence account for about 70% of the total supernatant sig-
nal. This shows that VP3 could be efficiently secreted in L.
lactis although some degradation occurred.
(iii) Cell wall targeting. Cell wall targeting of VP3 was as-
sessed in L. lactis expressing the spUsp45-vp3-cwaM6 fusion.
CWAM6 comprises (i) 35 amino acids that are necessary for
anchoring and are cleaved off upon tethering of the protein to
the peptidoglycan and (ii) a 105-residue upstream sequence
used as a spacer to display the protein of interest outside of the
cell wall layer (10). Western blot analysis revealed bands in the
cell wall fraction in the range of 35 to 47 kDa; very little VP3
protein was detected in the supernatant (Fig. 2C). The higher
band in the cell wall fraction is likely to correspond to the
full-length anchored VP3 fusion (theoretical molecular mass,
49 kDa); the other bands might result from proteolysis, as
previously observed when Nuc was expressed at the surface of
L. lactis (10). This result shows that some proportion of VP3
could be targeted to the L. lactis cell wall. Nevertheless, the
majority (about 80%) of signals were present in the protoplast
fraction (Fig. 2C). These bands probably correspond to the
SPUsp45-VP3-CWAM6 precursor (the higher band) and to deg-
radation products. Comparison of the secreted (Fig. 2B) and
anchored (Fig. 2C) forms of VP3 indicates that a smaller
proportion of total VP3 is cell wall anchored than secreted.
In summary, IBDV VP3 antigen can be targeted to three cell
compartments in L. lactis. VP3 could be stably produced in the
cytoplasm. When fused to suitable signals, about 80% of the
VP3 could be secreted and about 20% could be anchored to
the cell wall, although some proteolysis occurred in both cases.
The protocol used for protein fractionation appeared efficient,
as each VP3 species that was targeted to a defined cell com-
partment provided a typical pattern that was not found in the
other fractions. This demonstrates that no contamination be-
tween the different fractions occurred.
VP2 failed to be secreted in L. lactis. The vp2 gene was
cloned in frame into cytoplasmic and secretion vectors, and its
expression in L. lactis was analyzed by Western blotting of
fractionated samples with antibodies raised against VP2. As
expected, cells harboring the cytoplasmic vector generated a
unique band in the protoplast fraction (data not shown). How-
ever, in cells harboring the secretion vector, the only detected
band was in the protoplast fraction as well (Fig. 3A); it mi-
grated at the expected position of SPUsp45-VP2 (54 kDa). No
signal was present in either the cell wall or the supernatant
fraction. This result suggests that VP2 could not be exported in
L. lactis. As VP2 is naturally expressed in a cytoplasmic context
in IBDV, one can imagine that despite the addition of SPUsp45,
VP2 remained in a state incompetent for membrane translo-
cation.
The fusion of VP2 to staphylococcal Nuc allows its secretion
and cell wall anchoring. We suspected that fusion of VP2 to a
readily secreted protein, staphylococcal Nuc, could enhance
secretion efficiency. To test this possibility, we expressed an
spUsp45-nuc-vp2 fusion in L. lactis. Western blot analysis with
antibodies raised against Nuc showed one major band and a
few faster-migrating weak bands in the supernatant (Fig. 3B).
The distribution of the fusion protein was about 80 and 20% in
the protoplast and supernatant fractions, respectively. This
suggests that fusion of VP2 with Nuc facilitates its export.
Nevertheless, the detected species in both the protoplast and
supernatant fractions were smaller than the expected sizes
(theoretical molecular mass of 69 kDa for Nuc-VP2), suggest-
ing that degradation occurs. As degradation products are
mainly observed in the protoplast fraction, it is likely that
Nuc-VP2 is degraded before its export. To further characterize
the degradation events, we blotted the same membrane with
antibodies raised against VP2. No signal was detected (data
not shown), suggesting that the proteolysis targets the VP2
sequence.
For assessment of VP2 targeting to the L. lactis cell wall, we
FIG. 2. Analysis of L. lactis strains expressing VP3. Proteins from log-phase growing cultures were fractionated and analyzed by Western
blotting with 9.7 anti-VP3 monoclonal antibodies. spUsp45, signal peptide from the Usp45 preprotein; cwaM6, cell wall anchor domain from the M6
preprotein; PP, protoplast; CW, cell wall; SN, supernatant; IBDV, purified IBDV. The positions of full-length VP3 and molecular mass standards
(kilodaltons) are indicated.
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constructed the spUsp45-nuc-vp2-cwaM6 fusion. Its expression
product was analyzed in L. lactis by Western blotting with
antibodies against Nuc. The protoplast fraction produced one
strong band that corresponds to the 86-kDa precursor protein
SPUsp45-Nuc-VP2-CWAM6 (Fig. 3C). The cell wall fraction
displayed a strong band of the size expected for the anchored
species (84 kDa), which represented 20% of the signals de-
tected in the three cell compartments. This proportion is the
same as that of secreted Nuc-VP2 obtained as described above,
which suggests that, once translocated across the membrane,
the Nuc-VP2 fusion is efficiently targeted to the cell wall of L.
lactis. Interestingly, anchored Nuc-VP2 appears to be more
stable than the secreted fusion since its migration corresponds
to the full-size protein. Possibly, the addition of CWAM6 partly
protects VP2 against proteolysis. However, some cell surface
proteolysis may occur, as suggested by the presence of a low-
molecular-weight compound in the supernatant fraction.
Three factors suggest that this proteolysis occurs within
theVP2 sequence. First, this sequence is, as shown above,
highly susceptible to proteolysis. Second, the degradation com-
pound still reacts with Nuc antibodies. Third, the topology of
the Nuc-VP2-CWAM6 fusion strongly suggests that its release
into the supernatant results from C-terminal degradation as it
is anchored to the cell wall by its C terminus. Since little
proteolysis within CWAM6 occurred in the above-described
studies with VP3 (Fig. 2C), VP2 was probably the major target
for proteolysis.
Chicken immune response to recombinant lactococci. The
immunogenicity of recombinant L. lactis strains expressing
IBDV antigens or Nuc was evaluated after oral administration
to chickens. The birds received 109 cells daily for 5 successive
days, and the same administration protocol was repeated 2
weeks later. Specific serum IgG production was analyzed at
days 0, 14, and 21 following the first administration. The strain
expressing the cell wall-anchored Nuc-VP2 fusion induced a
weak but significant IgG response against Nuc (Fig. 4). This
response appeared at day 14 after the first administration (P 
0.02) and increased at day 21 postimmunization (P  0.016),
which corresponds to 1 week after the booster immunization
(Fig. 4). However, we did not detect any serum IgG response
against VP2 (data not shown). Also, no immune response was
detected after immunization of chickens with L. lactis express-
ing the other antigens tested in this study (data not shown).
DISCUSSION
In a preceding work, we have designed a system for targeting
of a reporter protein to the cytoplasm, the cell wall, or the
supernatant culture of LAB (10). With this system, our ulti-
mate objective is to study the host immune response in relation
to antigen localization in the LAB vehicle. In the present work,
we decided to target the two major antigens from chicken
IBDV to different cell compartments of L. lactis and use the
recombinant lactococci to immunize chickens by oral admin-
istration.
Targeting of IBDV antigens in L. lactis. (i) VP2 and VP3 are
stable in the cytoplasm of L. lactis. VP2 and VP3 were suc-
cessfully produced in the cytoplasm and appeared as unique
bands of the expected sizes, suggesting that no proteolysis
FIG. 3. Analysis of L. lactis strains expressing VP2 fusions. Proteins from log-phase growing cultures were fractionated and analyzed by Western
blotting with anti-VP2 (A) or anti-Nuc (B and C) antibodies. spUsp45, signal peptide from the Usp45 preprotein; cwaM6, cell wall anchor domain
from the M6 preprotein; PP, protoplast; CW, cell wall; SN, supernatant; IBDV, purified IBDV; Nuc, S. aureus nuclease. The positions of pre-VP2
(pVP2) and VP2 and molecular mass standards (kilodaltons) are indicated.
FIG. 4. Serum IgG response to Nuc. Ten chickens were immunized
with 109 bacteria (black dots, negative control [strain VE5505 contain-
ing pVE5502]; white dots, strain VE5671 containing pVE5540 and
producing anchored Nuc-VP2) for 5 consecutive days starting at days
0 and 14 (indicated by filled triangles). Individual serum samples were
collected at days 0 (before the first administration), 14, and 21 and
tested by enzyme-linked immunosorbent assay for NucA-specific IgG.
*, P  0.02; **, P  0.016 (Student’s t test). A.U.450nm, units of
absorption at 450 nm.
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occurred. We attribute this stability of VP2 and VP3 in the
cytoplasm to their rapid folding, which would provide them
with a structure resistant to cytoplasmic proteases. Indeed, the
compact conformational structure and multimerization of VP2
and VP3 are supported by studies with yeast (45). However, as
previously observed with other proteins in L. lactis, VP2 and
VP3 were produced at a lower yield than their secreted and cell
wall-anchored counterparts (Fig. 2 and 3) (3, 10, 12, 37). No
explanation for this finding has been found.
(ii) Secretion of NNSP versus their degradation. Naturally
nonsecreted proteins (NNSP) are known to be difficult to se-
crete. This is attributed to their tendency to fold rapidly in the
cytoplasm, which prevents their translocation across the cyto-
plasmic membrane (35). A first way to delay their folding and
keep them in the unfolded state required for translocation is to
fuse them with a signal peptide. In an attempt to drive secre-
tion of the two NNSP VP2 and VP3, we used the signal peptide
from Usp45 (the most-secreted protein in L. lactis), followed
by negatively charged amino acids downstream of the cleavage
site. This combination has previously been shown to be the
most efficient in LAB for secretion of heterologous naturally
secreted proteins (10). With this system, efficient secretion of
VP3 (80%) was obtained. This is a particularly high level for an
NNSP compared with other viral proteins that were secreted
much less in L. lactis (12, 37). On the other hand, fusion of VP3
with SPUsp45 also induced VP3 degradation both at the pre-
cursor level in the protoplast and at the mature-protein level in
the extracellular medium. As native VP3 was stable in the
cytoplasm of L. lactis (Fig. 2A), we attribute the cytoplasmic
degradation to the addition of SPUsp45, which would impede
VP3 folding, rendering it more susceptible to proteolysis. It is
likely that cytoplasmic and extracellular degradation is medi-
ated by ClpP and HtrA, two housekeeping proteases located in
the cytoplasm and on the outer side of the membrane of L.
lactis, respectively (14, 34).
Fusion of VP2 to SPUsp45 failed to drive VP2 secretion (Fig.
3A). This suggests that this Usp45 signal peptide is not suffi-
cient to prevent VP2 folding and/or multimerization in the
cytoplasm of L. lactis. It has been shown in both Escherichia
coli and Bacillus subtilis that the protein-folding process can be
further delayed (and protein secretion can be improved) by
overexpression of chaperones proteins (40, 51). We first chose
another strategy, which consisted of fusing VP2 to the C ter-
minus of naturally secreted S. aureus Nuc. Our rationale was
based on the postulate that addition of Nuc might delay the
folding of VP2, thus maintaining the fusion protein in an ex-
port-competent state. To a certain extent, this strategy ap-
peared successful, allowing a secretion efficiency of 20% for
the Nuc-VP2 fusion. This suggests that an NNSP such as VP2
that is totally recalcitrant to translocation in its native form can
be partly carried through the secretion machinery when it is
fused to a naturally secreted protein such as Nuc. This may find
many applications in the development of protein delivery by
LAB, as some candidate proteins, including antigens and en-
zymes, are not naturally secreted in their native organism. An
adverse effect of the partial secretion of Nuc-VP2 was observed
in protein degradation that concerned the VP2 moiety of the
fusion. Altogether, these results show that there are conflicting
interests in retarding protein folding; i.e., translocation may
occur, but the unfolded protein is more prone to proteolysis.
(iii) Cell wall anchoring of NNSP and protection against
proteolysis. Both Nuc-VP2 and VP3 could be anchored to the
cell wall of L. lactis. Although the proportion of precursor
processed to the cell wall (20%) was the same for both anti-
gens, we believe that the respective bottlenecks hampering cell
wall anchoring of VP2 and VP3 are different. In the case of
Nuc-VP2, we observed the same level of processing in the case
of secretion and cell wall anchoring. As membrane transloca-
tion is a prerequisite for cell wall anchoring, we believe that, in
the case of Nuc-VP2, the limiting step for cell wall anchoring
is translocation of the precursor through the membrane. In
contrast, in the case of VP3, the secretion level was 80% and
the cell wall-anchoring level was 20%. This is reminiscent of
the observation previously made with Nuc (10). In this case, we
showed that the defect in cell wall anchoring is due not to a
translocation defect but rather to too low an activity of sortase,
the transpeptidase tethering the protein to the cell wall. We
believe that the same phenomenon explains why some VP3
cannot anchor to the cell wall. Probably, the sortase level in L.
lactis is sufficient to anchor the low level of exported Nuc-VP2
but insufficient to anchor VP3, which is exported at a higher
level.
Interestingly, cell wall anchoring of Nuc-VP2 allowed its
partial protection against proteolysis. Whereas all of the Nuc-
VP2 secreted had the VP2 portion truncated, most of the cell
wall-anchored fusion appeared as the entire Nuc-VP2 fusion.
Although we have no explanation for this observation, it could
be valuable to stabilize proteins that are highly susceptible to
proteolysis when they are exported outside the cell.
Serum antibody response to oral administration of IBDV
antigen-producing L. lactis. IBDV antigen-producing lacto-
cocci were used to investigate the potential of L. lactis for
vaccine delivery into chickens. This represents a first step to-
ward the development of a new strategy for vaccination against
IBDV. Such a vaccination strategy, with LAB as the vehicle for
oral administration of the vaccine through food or water,
would be highly attractive because of its low cost, its safety, and
the absence of immunosuppression.
We chose VP2 and VP3 as antigens to be expressed in L.
lactis as these proteins are constituents of the IBDV capsid and
represent 90% of the total IBDV proteins (11). VP2 contains
the major epitopes that elicit neutralizing antibodies (13),
while VP3 has been reported to bear minor neutralizing sites
(20).
The lactococcal strains designed and characterized as de-
scribed above were used for oral vaccination of 28-day-old
specific-pathogen-free chickens. It is noteworthy that strains
expressing exported forms (secreted or cell wall anchored) of
VP2 and VP3 also accumulated significant amounts of antigen
in their protoplast. Consequently, antigens were, in fact, lo-
cated in two cell compartments. Following oral vaccination of
chickens, only bacteria producing an anchored Nuc-VP2 fusion
induced a systemic and specific response against Nuc but not
against VP2. This is the first demonstration that oral adminis-
tration of antigen-producing LAB can promote an immune
response in production animals such as chickens, as the few
studies performed in this field have been conducted with mice
(29). However, these results raise two questions. (i) Why did
only Nuc fused to VP2 and cell wall anchored induce an im-
mune response, and (ii) why did only Nuc, and not VP2 or
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VP3, induce an immune response? It has been shown previ-
ously that cell wall-anchored antigens are more immunogenic
in mice than are their cytoplasmic or secreted counterparts (36,
50). A hypothesis is that the expression level of the designed
fusion genes is situated at the threshold required to elicit an
immune response. Therefore, only the most immunogenic
form, i.e., the cell wall-anchored form, of Nuc-VP2 would have
allowed an immunological response of the chickens. A param-
eter other than the expression level did occur as lactococci
expressing cell wall-anchored Nuc on its own with the same
expression system were not immunogenic. Possibly, this may be
due to the topology of the Nuc-VP2 fusion at the cell wall. As
the fusion is anchored by its C terminus, VP2 could have a
spacer role allowing the Nuc moiety to be displayed outside the
peptidoglycan. This would allow better contact with immune
cells. In this case, it would also explain why no response against
VP2 and VP3 was observed as these antigens would be buried
in the bacterial peptidoglycan layer.
Another possible explanation is that the absence of serum
antibody reflects differential mucosal and systemic immune
responses. This hypothesis is based on recent observations in
mice after oral administration of L. lactis cells expressing bo-
vine -lactoglobulin (7). Significant levels of specific anti -lac-
toglobulin IgA were found in feces, while all of the Ig classes
tested (IgA, IgG1, IgG2a, and IgE) were absent in serum. A
similar imbalance toward an IgA response might account for
our results.
In the emerging field of antigen delivery by LAB, further
work is needed to better understand and improve the mecha-
nisms governing chicken immune responses. Several lines of
improvement exist, including (i) antigen stabilization in LAB
by down regulation of housekeeping protease genes (15, 34),
(ii) better protein export by overexpression of chaperones, and
(iii) improvement of protein anchoring to the cell wall by
sortase overexpression. Also, improvements in the interactions
between the bacteria and the host immune system will consist
of (i) coexpression of both antigens and adjuvants in LAB as L.
lactis is able to produce fully active cytokines (2, 43, 44) and (ii)
the use of LAB able to colonize the chicken gut (17, 18).
Probably, a combination of improvements along these lines will
be necessary to make LAB serious candidates for live-vaccine
development.
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